



## Curriculum Vitae

Personal information **Svein Rune Andersen**

### Work experience

---

Scientific Director - Vaccines, Norwegian Institute of Public Health 20.06.22 - to date  
Scientific Director - Vaccines, Norwegian Medicines Agency 19.02.21 - 19.6.22  
Head of Regulatory Affairs - Europe, CEPI 18.02.19 – 19.02.21  
Scientific Director, Member of CHMP,  
Norwegian Medicines Agency, Oslo 17.01.17-18.02.19  
Head of Section/Scientific Director,  
Section for Biological Medicines and Vaccines 16.07.09- 16.01.17  
Senior adviser, Norwegian Medicines Agency, Oslo 22.04.03-15.07.09  
Patent attorney, Tandbergs Patentkontor AS, Oslo 01.06.02-21.04.03  
Research Scientist, The Edward Jenner Institute for  
Vaccine Research, Compton, Berkshire, England 01.07.98-31.05.02  
Research scientist, National Veterinary Institute, Oslo 02.09.96-31.06.98  
Research scientist/Dr. Scient student, NIPH, Oslo 23.07.91-31.08.96  
Medical Laboratory Engineer, NIPH, Oslo 18.05.89-30.06.91  
Medical Laboratory Engineer, NIPH, Oslo, 16.09.85-12.01.87  
Medical Laboratory Engineer, Microbiology Dept. Ullevål hospital, Oslo 03.06.85-  
05.09.85

### Education and training

---

**Dr. scient.** within Biochemistry/Immunology/Vaccinology, Institute of Pharmacy,  
Faculty 1997  
of Mathematics and Natural Science, University of Oslo/ National Institute of Public  
Health,  
Oslo  
**Cand. scient.**, Institute of Biochemistry, University of Oslo/NIPH, Oslo 1990  
(*Master of Science*).  
**Engineer, Oslo College of Engineering,**  
Disciplines: microbiology, immunology, and pathology. 1985

### Additional information

---

#### Publications

**Paul-Henri Lambert, Donna M. Ambrosino, Svein R. Andersen, Ralph S. Baric, Steven B. Black, Robert T. Chen, Cornelia L. Dekker, Arnaud M. Didierlaurent, Barney S. Graham, Samantha D. Martin, Deborah C. Molrine, Stanley Perlman, Philip A. Picard-Fraser, Andrew J. Pollard, Chuan Qin, Kanta Subbarao, Jakob P. Cramer**

Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.  
Vaccine 2020 Jun 26;38(31):4783-4791

**Bernasconi V, Kristiansen PA, Whelan M, Román RG, Bettis A, Yimer SA, Gurry C, Andersen SR, Yeskey D, Mandi H, Kumar A, Holst J, Clark C, Cramer JP, Røttingen J-A, Hatchett R, Saville M, Norheim G**

Developing vaccines against epidemic-prone emerging infectious diseases  
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2020 Jan;63(1):65-

**Wagner L, Isbrucker R, Loch C, Arciniega J, Costanzo A, McFarland R, Oh H, Hoonakker M, Descamps J, Andersen SR, Gupta RK, Markey RK, Chapsal JM, Lidster K, Casey K, Allen D.**

In search of acceptable alternatives to the murine histamine sensitisation test (HIST): what is possible and practical?

Pharmeur. Bio, December 2016: 82-101

**Etchart N, Baaten B, Andersen SR, Hyland L, Wong SY, Hou S.**

Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge.

Eur. J. Immunol. 2006; **36**(5):1136-44.

**Guthrie T, Wong SY, Liang B, Hyland L, Hou S, Hoiby EA, Andersen SR.**

Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from *Neisseria meningitidis*.

Infect. Immun. 2004; **72**(5):2528-37.

**Tollersrud T, Norstebo PE, Engvik JP, Andersen SR, Reitan LJ, Lund A.**

Antibody responses in sheep vaccinated against *Staphylococcus aureus* mastitis: a comparison of two experimental vaccines containing different adjuvants.

Vet. Res. Commun. 2002; **26**(8):587-600.

**Andersen SR, Guthrie T, Guile GR, Kolberg J, Hou S, Hyland L, Wong SY.**

Cross-reactive polyclonal antibodies to the inner core of Lipopolysaccharide from *Neisseria meningitidis*.

Infect. Immun. 2002; **70**(3):1293-300.

**Tollersrud T, Zernichow L, Andersen SR, Kenny K, Lund A.**

*Staphylococcus aureus* capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle.

Vaccine. 2001; **19**(28-29):3896-903.

**Dixon GL, Newton PJ, Chain BM, Katz D, Andersen SR, Wong S, van der Ley P, Klein N, Callard RE.**

Dendritic cell activation and cytokine production induced by group B *Neisseria meningitidis*: interleukin-12 production depends on lipopolysaccharide expression in intact bacteria.

Infect Immun. 2001; **69**(7):4351-7.

**Uronen H, Williams AJ, Dixon G, Andersen SR, Van Der Ley P, Van Deuren M, Callard RE, Klein N.**

Gram-negative bacteria induce proinflammatory cytokine production by monocytes in the absence of lipopolysaccharide (LPS).

Clin Exp Immunol. 2000; **122**(3):312-5.

**Berstad AK, Andersen SR, Dalseg R, Dromtorp S, Holst J, Namork E, Wedege E, Haneberg B.**

Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine.

Vaccine. 2000; **18**(18):1910-9.

**Dixon GL, Heyderman RS, Kotovicz K, Jack DL, Andersen SR, Vogel U, Frosch M, Klein N.**

Endothelial adhesion molecule expression and its inhibition by recombinant bactericidal/permeability-increasing protein are influenced by the capsulation and

lipooligosaccharide structure of *Neisseria meningitidis*.  
*Infect Immun.* 1999; **67**(11):5626-33.

**Oftung F, Lovik M, Andersen SR, Froholm LO, Bjune G.**

A mouse model utilising human transferrin to study protection against *Neisseria meningitidis* serogroup B induced by outer membrane vesicle vaccination.  
*FEMS Immunol Med Microbiol.* 1999; **26**(1):75-82.

**Haneberg B, Dalseg R, Oftung F, Wedege E, Hoiby EA, Haugen IL, Holst J, Andersen SR, Aase A, Meyer Naess L, Michaelsen TE, Namork E, Haaheim LR.**

Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant.  
*Dev. Biol. Stand.* 1998; **92**:127-33.

**Haneberg B, Dalseg R, Wedege E, Hoiby EA, Haugen IL, Oftung F, Andersen SR, Naess LM, Aase A, Michaelsen TE, Holst J.**

Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.  
*Infect. Immun.* 1998; **66**(4):1334-41.

**Rune Andersen S, Kolberg J, Hoiby EA, Namork E, Caugant DA, Oddvar Froholm L, Jantzen E, Bjune G.** Lipopolysaccharide heterogeneity and escape mechanisms of *Neisseria meningitidis*: possible consequences for vaccine development.  
*Microb. Pathog.* 1997; **23**(3):139-55.

**Andersen SR, Bjune G, Hoiby EA, Michaelsen TE, Aase A, Rye U, Jantzen E.**

Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B *Neisseria meningitidis*: effect of the carbohydrate chain length on the immune response.  
*Vaccine.* 1997; **15**(11):1225-34.

**van der Ley P, Kramer M, Steeghs L, Kuipers B, Andersen SR, Jennings MP, Moxon ER, Poolman JT.**

Identification of a locus involved in meningococcal lipopolysaccharide biosynthesis by deletion mutagenesis.  
*Mol Microbiol.* 1996; **19**(5):1117-25.

**Andersen SR, Bryn K, Thorseng K, Jantzen E.**

Heterogeneity of lipopolysaccharides of *Neisseria meningitidis* revealed by thin-layer chromatography combined with monoclonal antibodies.  
*J. Microbiol. Methods* 1996; **25**: 187-194.

**Andersen SR, Bjune G, Lyngby J, Bryn K, Jantzen E.**

Short-chain lipopolysaccharide mutants of serogroup B *Neisseria meningitidis* of potential value for production of outer membrane vesicle vaccines.  
*Microb. Pathog.* 1995; **19**(3):159-68.

#### Projects

#### Memberships

#### Other Relevant Information

EMA Committes/working parties (up until 18.02.2019):

- Vaccine Working Party: observer from 2014 to 2016 and core member since April 2016. Elected as vice-chair in March 2017.
- Biologics Working Party: Norwegian delegate from 2007 to 2015 and member

of BWP's vaccine core group since 2015.

- Joint Expert group on the 3Rs 2011-2017
- CHMP 17.01.17-18.02.19

#### EDQM

- Expert group 15 - Human vaccines and sera, European Pharmacopeia: Member since 2007,  
Chair from November 2016 – to date.
- Member of Biological Standardisation Program Steering Committee from 2010- to date.
- Member of mRNA vaccine Working party 2022-to date.